心力衰竭SGLT2抑制剂临床应用的中国专家共识

2022-07-07 中国心力衰竭中心联盟专家委员会临床心血管病杂志

钠-葡萄糖协同转运蛋白-2（SGLT2）抑制剂已经被推荐为治疗心力衰竭的新四联药物之一。本专家共识重点介绍SGLT2抑制剂治疗心力衰竭的作用机制、药物代谢动力学特征、循证医学证据以及临床实践经验,为中

中文标题：

发布机构：

中国心力衰竭中心联盟专家委员会

发布日期：

2022-07-07

简要介绍：

钠-葡萄糖协同转运蛋白-2（SGLT2）抑制剂已经被推荐为治疗心力衰竭的新四联药物之一。本专家共识重点介绍SGLT2抑制剂治疗心力衰竭的作用机制、药物代谢动力学特征、循证医学证据以及临床实践经验,为中国心力衰竭患者提供临床应用的规范与建议。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=a082c1c002512604, title=心力衰竭SGLT2抑制剂临床应用的中国专家共识, enTitle=, guiderFrom=临床心血管病杂志, authorId=0, author=, summary=钠-葡萄糖协同转运蛋白-2（SGLT2）抑制剂已经被推荐为治疗心力衰竭的新四联药物之一。本专家共识重点介绍SGLT2抑制剂治疗心力衰竭的作用机制、药物代谢动力学特征、循证医学证据以及临床实践经验,为中, cover=https://img.medsci.cn/20220707/1657190791682_5579292.png, journalId=0, articlesId=null, associationId=2917, associationName=中国心力衰竭中心联盟专家委员会, associationIntro=中国心力衰竭中心联盟专家委员会, copyright=0, guiderPublishedTime=Thu Jul 07 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #666666;">钠-葡萄糖协同转运蛋白-2（SGLT2）抑制剂已经被推荐为治疗心力衰竭的新四联药物之一。本专家共识重点介绍SGLT2抑制剂治疗心力衰竭的作用机制、药物代谢动力学特征、循证医学证据以及临床实践经验,为中国心力衰竭患者提供临床应用的规范与建议。 </span></p>, tagList=[TagDto(tagId=335, tagName=心力衰竭), TagDto(tagId=20298, tagName=SGLT2抑制剂)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3194, appHits=194, showAppHits=0, pcHits=879, showPcHits=2984, likes=0, shares=36, comments=6, approvalStatus=1, publishedTime=Sat Jul 09 09:45:00 CST 2022, publishedTimeString=2022-07-07, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=FUNNYMAN, createdTime=Thu Jul 07 18:47:17 CST 2022, updatedBy=6459136, updatedName=艺玮, updatedTime=Sat Jan 06 20:28:25 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=心力衰竭SGLT2抑制剂临床应用的中国专家共识.pdf)])

心力衰竭SGLT2抑制剂临床应用的中国专家共识.pdf

下载请点击：

评论区 (5)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1241040, encodeId=5aec1241040c5, content=积分不够怎么办 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21ca8293754, createdName=ms2000000015251011, createdTime=Thu Aug 25 23:02:52 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240032, encodeId=a0c8124003213, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bce85595770, createdName=罗正琪, createdTime=Sat Aug 20 23:10:55 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239656, encodeId=d95e12396560f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb038267024, createdName=ms9000001762356548, createdTime=Fri Aug 19 07:36:37 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232135, encodeId=5ac31232135c6, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88ba5447974, createdName=ms7000001124466419, createdTime=Tue Jul 12 23:22:57 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
2022-08-25 ms2000000015251011

积分不够怎么办

36 1

展开1条回复
[GetPortalCommentsPageByObjectIdResponse(id=1241040, encodeId=5aec1241040c5, content=积分不够怎么办 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21ca8293754, createdName=ms2000000015251011, createdTime=Thu Aug 25 23:02:52 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240032, encodeId=a0c8124003213, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bce85595770, createdName=罗正琪, createdTime=Sat Aug 20 23:10:55 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239656, encodeId=d95e12396560f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb038267024, createdName=ms9000001762356548, createdTime=Fri Aug 19 07:36:37 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232135, encodeId=5ac31232135c6, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88ba5447974, createdName=ms7000001124466419, createdTime=Tue Jul 12 23:22:57 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
2022-08-20 罗正琪

非常实用

49 0
[GetPortalCommentsPageByObjectIdResponse(id=1241040, encodeId=5aec1241040c5, content=积分不够怎么办 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21ca8293754, createdName=ms2000000015251011, createdTime=Thu Aug 25 23:02:52 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240032, encodeId=a0c8124003213, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bce85595770, createdName=罗正琪, createdTime=Sat Aug 20 23:10:55 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239656, encodeId=d95e12396560f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb038267024, createdName=ms9000001762356548, createdTime=Fri Aug 19 07:36:37 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232135, encodeId=5ac31232135c6, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88ba5447974, createdName=ms7000001124466419, createdTime=Tue Jul 12 23:22:57 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
2022-08-19 ms9000001762356548

学习

48 0
[GetPortalCommentsPageByObjectIdResponse(id=1241040, encodeId=5aec1241040c5, content=积分不够怎么办 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21ca8293754, createdName=ms2000000015251011, createdTime=Thu Aug 25 23:02:52 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240032, encodeId=a0c8124003213, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bce85595770, createdName=罗正琪, createdTime=Sat Aug 20 23:10:55 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239656, encodeId=d95e12396560f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb038267024, createdName=ms9000001762356548, createdTime=Fri Aug 19 07:36:37 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232135, encodeId=5ac31232135c6, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88ba5447974, createdName=ms7000001124466419, createdTime=Tue Jul 12 23:22:57 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
2022-07-12 ms7000001124466419

非常实用

45 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

心血管指南

心力衰竭SGLT2抑制剂临床应用的中国专家共识

相关指南

科室

工具

服务